Pharma BD Deal Intelligence
A rare buy-and-it-worked story: Bayer's $240M-upfront, ~$600M consolidation of BlueRock's iPSC platform delivered a Phase III Parkinson's readout with the first exPDite-2 patient dosed in September 2025 and FDA RMAT in hand, though full approval remains years off.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Bayer paid $240M upfront plus up to $360M milestones to consolidate full ownership of BlueRock; the deal extends Bayer's cell-therapy thesis from the Versant…
iPSC-derived neurons solve the variability problems that plagued earlier fetal-tissue transplantation; the Bayer deal 'signals major pharmaceutical confidence…
FDA grants Orphan Drug Designation to OpCT-001 for retinitis pigmentosa (Jan 22, 2026); OpCT-001 also holds FDA Fast Track (Feb 2025).
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Bayer acquired the remaining ~59.2% of BlueRock Therapeutics it did not already own for $240M upfront plus up to $360M in milestones (~$600M total); the deal closed August 13, 2019. BlueRock's iPSC-derived cell-therapy platform engineers replacement cells for disease. As of 2026 the platform has materially advanced: lead asset bemdaneprocel (BRT-DA01), iPSC-derived dopaminergic neurons for Parkinson's disease, began the registrational Phase III exPDite-2 trial (~102 patients, randomized double-blind sham-surgery-controlled) with the first patient treated in September 2025, and holds FDA Fast Track (2021), RMAT (2024) and Japan SAKIGAKE (Dec 2025) designations. A second asset, OpCT-001, an iPSC-derived photoreceptor cell therapy for primary photoreceptor disease (retinitis pigmentosa), entered a Phase 1/2a trial (first patient July 2025) and received FDA Orphan Drug Designation (Jan 2026), extending the platform from neurology into ophthalmology.
Assessment window: 5yr post-close.
90K US cases/yr · $82.2B US annual economic burden of Parkinson's (healthcare + indirect costs)
Parkinson's disease is a progressive neurodegenerative disorder driven by loss of dopaminergic neurons in the substantia nigra, producing motor symptoms (tremor, rigidity, bradykinesia) and non-motor features (cognitive decline, autonomic dysfunction). Existing therapies—levodopa, dopamine agonists, MAO-B inhibitors, deep brain stimulation—manage symptoms but do not slow neurodegeneration; by diagnosis, ~50% of dopamine-producing neurons are already lost, leaving a clear gap for disease-modifying or restorative therapies.
Symptomatic Parkinson's care is dominated by levodopa-based regimens (Sinemet, Rytary, AbbVie's Duopa/Vyalev) plus dopamine agonists (Mirapex, Neupro) and MAO-B inhibitors (Azilect, Xadago). Disease-modification programs have repeatedly failed (e.g., Biogen/Denali's LRRK2 partnership, Roche/Prothena's prasinezumab missed primary endpoints). Cell therapy aims to replace lost dopamine neurons rather than augment remaining ones: BlueRock's lead program (later DA01/bemdaneprocel) uses iPSC-derived dopaminergic precursors implanted into the putamen, competing with Aspen Neuroscience's autologous iPSC approach and academic embryonic stem-cell programs (Kyoto University, Memorial Sloan Kettering/BlueRock collaboration). Bayer's $600M acquisition consolidated full ownership of an iPSC platform also targeting heart failure (cardiomyocyte regeneration) and autoimmune disease, signaling pharma's willingness to bet on regenerative medicine despite manufacturing complexity. The deal reframes Parkinson's commercial competition from chronic symptomatic management to potentially durable cell-replacement, with iPSC technology offering scalable allogeneic supply versus prior fetal-tissue grafts. Source: https://scienceofparkinsons.com/2019/08/18/bluerock/
First patient treated (Sept 2025) in BlueRock's pivotal Phase III exPDite-2 trial of bemdaneprocel (BRT-DA01), iPSC-derived dopaminergic neurons for Parkinson's disease (~102 pts, randomized double-blind sham-surgery-controlled). Asset holds FDA Fast Track (2021), RMAT (2024) and Japan SAKIGAKE designation (Dec 2025) — validating Bayer's 2019 BlueRock acquisition thesis.
OpCT-001, BlueRock's iPSC-derived photoreceptor cell therapy, received FDA Orphan Drug Designation for retinitis pigmentosa (Jan 22, 2026); first patient was dosed in the Phase 1/2a CLARICO trial in July 2025. Extends the BlueRock iPSC platform from neurology into ophthalmology.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / BlueRock Therapeutics LP (this deal) | 2019 | $600M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2019 deals · Bayer AG deals · Cardiovascular deals